Signal Transduction Pathways in Cancer Development and as Targets for Cancer Prevention

Progress in Nucleic Acid Research and Molecular Biology

Volumn 79, Issue , 2005, Pages 237-297

  Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC; HISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

ANIMAL; APOPTOSIS; CELL TRANSFORMATION; DISEASE MODEL; DRUG DESIGN; GENETICS; HUMAN; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; RADIATION EXPOSURE; REVIEW; SIGNAL TRANSDUCTION; ULTRAVIOLET RADIATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENIC; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; HISTONES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; ULTRAVIOLET RAYS;

EID: 23944524392     PISSN: 00796603     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6603(04)79005-4     Document Type: Review

References (378)

1. Dong Z., Cmarik J.L., Wendel E.J., and Colburn N.H. Differential transformation efficiency but not AP-1 induction under anchorage-dependent and -independent conditions. Carcinogenesis 15 (1994) 1001-1004
2. Dong Z., and Cmarik J.L. Harvesting cells under anchorage-independent cell transformation conditions for biochemical analyses. Sci STKE, (2002) PL7
3. Colburn N.H., Former B.F., Nelson K.A., and Yuspa S.H. Tumour promoter induces anchorage independence irreversibly. Nature 281 (1979) 589-591
4. Colburn N.H., Wendel E.J., and Abruzzo G. Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: Mitogen-resistant variants are sensitive to promotion. Proc. Natl. Acad. Sci. USA 78 (1981) 6912-6916
5. Strickland J., Sun Y., Dong Z., and Colburn N.H. Grafting assay distinguishes promotion-sensitive from promotion-resistant JB6 cells. Carcinogenesis 18 (1997) 1135-1138
6. Sun Y., Nakamura K., Hegamyer G., Dong Z., and Colburn N. No point mutation of Ha-ras or p53 genes expressed in preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants. Mol. Carcinog. 8 (1993) 49-57
7. Dong Z., Birrer M.J., Watts R.G., Matrisian L.M., and Colburn N.H. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc. Natl. Acad. Sci. USA 91 (1994) 609-613
8. Lavrovsky V., Dong Z., Ma W.Y., and Colburn N. Drug-induced reversion of progression phenotype is accompanied by reversion of AP-1 phenotype in JB6 cells. In Vitro Cell. Dev. Biol. Anim. 32 (1996) 234-237
9. Dong Z., Lavrovsky V., and Colburn N.H. Transformation reversion induced in JB6 RT101 cells by AP-1 inhibitors. Carcinogenesis 16 (1995) 749-756
10. Dong Z., Watts S.G., Sun Y., and Colburn N.H. Progressive elevation of AP-1 activity during preneoplastic-to neoplastic progression as modeled in mouse JB6 cell variants. Int. J. Oncol. 7 (1995) 359-364
11. Huang C., Zhang Q., Li J., Shi X., Castranova V., Ju G., Costa M., and Dong Z. Involvement of Erks activation in cadmium-induced AP-1 transactivation in vitro and in vivo. Mol. Cell Biochem. 222 (2001) 141-147
12. Huang C., Bode A.M., Chen N.Y., Ma W.Y., Li J., Nomura M., and Dong Z. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res. 21 (2001) 261-267
13. Huang C., Li J., Chen N., Ma W., Bowden G.T., and Dong Z. Inhibition of atypical PKC blocks ultraviolet-induced AP-1 activation by specifically inhibiting ERKs activation. Mol. Carcinog. 27 (2000) 65-75
14. Huang C., Ma W.Y., Hanenberger D., Cleary M.P., Bowden G.T., and Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J. Biol. Chem. 272 (1997) 26325-26331
15. Zhong S., Quealy J.A., Bode A.M., Nomura M., Kaji A., Ma W.Y., and Dong Z. Organ-specific activation of activator protein-1 in transgenic mice by 12-o-tetradecanoylphorbol-13-acetate with different administration methods. Cancer Res. 61 (2001) 4084-4091
16. Zhong S.P., Ma W.Y., Quealy J.A., Zhang Y., and Dong Z. Organ-specific distribution of AP-1 in AP-1 luciferase transgenic mice during the maturation process. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280 (2001) R376-R381
17. Ding M., Dong Z., Chen F., Pack D., Ma W.Y., Ye J., Shi X., Castranova V., and Vallyathan V. Asbestos induces activator protein-1 transactivation in transgenic mice. Cancer Res. 59 (1999) 1884-1889
18. Ding M., Shi X., Dong Z., Chen F., Lu Y., Castranova V., and Vallyathan V. Freshly fractured crystalline silica induces activator protein-1 activation through ERKs and p38 MAPK. J. Biol. Chem. 274 (1999) 30611-30616
19. Barthelman M., Chen W., Gensler H.L., Huang C., Dong Z., and Bowden G.T. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res. 58 (1998) 711-716
20. Rincon M., and Flavell R.A. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. Embo J. 13 (1994) 4370-4381
21. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol. Ther. 54 (1992) 63-128
22. Agarwal R., and Mukhtar H. Cutaneous chemical carcinogenesis. In: Mukhtar H. (Ed). "Pharmacology of the Skin" (1992), CRC Press, Boca Raton, FL 434
23. Davis R.J. MAPKs: New JNK expands the group. Trends Biochem. Sci. 19 (1994) 470-473
24. Angel P., Hattori K., Smeal T., and Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55 (1988) 875-885
25. Kallunki T., Su B., Tsigelny I., Sluss H.K., Derijard B., Moore G., Davis R., and Karin M. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8 (1994) 2996-3007
26. Sanchez I., Hughes R.T., Mayer B.J., Yee K., Woodgett J.R., Avruch J., Kyriakis J.M., and Zon L.I. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372 (1994) 794-798
27. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 (1994) 841-852
28. Huang C., Ma W.Y., Li J., and Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 59 (1999) 3053-3058
29. Eferl R., and Wagner E.F. AP-1: A double-edged sword in tumorigenesis. Nature Rev. Cancer 3 (2003) 859-868
30. Angel P., and Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072 (1991) 129-157
31. Huang C., Chen N., Ma W.Y., and Dong Z. Vanadium induces AP-1- and NFkappB-dependent transcription activity. Int. J. Oncol. 13 (1998) 711-715
32. Ma W.Y., Huang C., and Dong Z. Inhibition of ultraviolet C irradiation-induced AP-1 activity by aspirin is through inhibition of JNKs but not erks or P38 MAP kinase. Int. J. Oncol. 12 (1998) 565-568
33. Barthelman M., Bair W.B., Stickland III K.K., Chen W., Timmermann B.N., Valcic S., Dong Z., and Bowden G.T. (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 19 (1998) 2201-2204
34. Chen W., Dong Z., Valcic S., Timmermann B.N., and Bowden G.T. Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line. Mol. Carcinog. 24 (1999) 79-84
35. Chen W., Borchers A.H., Dong Z., Powell M.B., and Bowden G.T. UVB irradiation-induced activator protein-1 activation correlates with increased c-fos gene expression in a human keratinocyte cell line. J. Biol. Chem. 273 (1998) 32176-32181
36. Nomura M., Ma W.Y., Huang C., Yang C.S., Bowden G.T., Miyamoto K., and Dong Z. Inhibition of ultraviolet B-induced AP-1 activation by theaflavins from black tea. Mol. Carcinog. 28 (2000) 148-155
37. Huang C., Ma W.Y., and Dong Z. The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells. Oncogene 18 (1999) 2828-2835
38. Dong Z., Huang C., Ma W.Y., Malewicz B., Baumann W.J., and Kiss Z. Increased synthesis of phosphocholine is required for UV-induced AP-1 activation. Oncogene 17 (1998) 1845-1853
39. Huang C., Ma W., Ding M., Bowden G.T., and Dong Z. Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. J. Biol. Chem. 272 (1997) 27753-27757
40. Huang C., Ma W., and Dong Z. Signal transduction through atypical PKCs, but not the EGF receptor, is necessary for UVC-induced AP-1 activation in immortal murine cells. Oncogene 14 (1997) 1945-1954
41. Huang C., Ma W.Y., Ryan C.A., and Dong Z. Proteinase inhibitors I and II from potatoes specifically block UV-induced activator protein-1 activation through a pathway that is independent of extracellular signal-regulated kinases, c-Jun N-terminal kinases, and P38 kinase. Proc. Natl. Acad. Sci. USA 94 (1997) 11957-11962
42. Huang C., Ma W., Bowden G.T., and Dong Z. Ultraviolet B-induced activated protein-1 activation does not require epidermal growth factor receptor but is blocked by a dominant negative PKClambda/iota. J. Biol. Chem. 271 (1996) 31262-31268
43. Huang C., Ma W.Y., and Dong Z. Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol. Cell. Biol. 16 (1996) 6427-6435
44. Chen N., Ma W.Y., and Dong Z. Inositol hexaphosphate inhibits ultraviolet B-induced signal transduction. Mol. Carcinog. 31 (2001) 139-144
45. Liu G., Chen N., Kaji A., Bode A.M., Ryan C.A., and Dong Z. Proteinase inhibitors I and II from potatoes block UVB-induced AP-1 activity by regulating the AP-1 protein compositional patterns in JB6 cells. Proc. Natl. Acad. Sci. USA 98 (2001) 5786-5791
46. Liu G., Ma W.Y., Bode A.M., Zhang Y., and Dong Z. NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2. J. Biol. Chem. 278 (2003) 2124-2130
47. Huang C., Ma W.Y., Dawson M.I., Rincon M., Flavell R.A., and Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc. Natl. Acad. Sci. USA 94 (1997) 5826-5830
48. Li J.J., Dong Z., Dawson M.I., and Colburn N.H. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res. 56 (1996) 483-489
49. Huang C., Ma W.-Y., and Dong Z. Inhibitory effects of ascorbic acid on AP-1 activity and transformation of JB6 cells. Int. J. Oncol. 8 (1996) 389-393
50. Dong Z., Crawford H.C., Lavrovsky V., Taub D., Watts R., Matrisian L.M., and Colburn N.H. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13- acetate-induced invasion in mouse keratinocytes. Mol. Carcinog. 19 (1997) 204-212
51. Huang C., Ma W.Y., Young M.R., Colburn N., and Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc. Natl. Acad. Sci. USA 95 (1998) 156-161
52. Watts R.G., Huang C., Young M.R., Li J.J., Dong Z., Pennie W.D., and Colburn N.H. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 17 (1998) 3493-3498
53. Chen N., Ma W.Y., She Q.B., Wu E., Liu G., Bode A.M., and Dong Z. Transactivation of the epidermal growth factor receptor is involved in 12-O-tetradecanoylphorbol-13-acetate-induced signal transduction. J. Biol. Chem. 276 (2001) 46722-46728
54. Pramanik R., Qi X., Borowicz S., Choubey D., Schultz R.M., Han J., and Chen G. p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun: The determinant roles of the isoforms in the p38 MAPK signal specificity. J. Biol. Chem. 278 (2003) 4831-4839
55. He Z., Cho Y.Y., Liu G., Ma W.Y., Bode A.M., and Dong Z. p38 mitogen-activated protein kinase regulation of JB6 Cl41 cell transformation promoted by epidermal growth factor. J. Biol. Chem. 278 (2003) 26435-26442
56. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270 (1995) 16483-16486
57. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
58. Huang C., Li J., Ma W.Y., and Dong Z. JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem. 274 (1999) 29672-29676
59. Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., and Davis R.J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15 (1996) 2760-2770
60. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., and Davis R.J. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 (1994) 1025-1037
61. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol. Rev. 79 (1999) 143-180
62. Ip Y.T., and Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK): From inflammation to development. Curr. Opin. Cell Biol. 10 (1998) 205-219
63. Kuan C.Y., Yang D.D., Samanta Roy D.R., Davis R.J., Rakic P., and Flavell R.A. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22 (1999) 667-676
64. Yang D.D., Kuan C.Y., Whitmarsh A.J., Rincon M., Zheng T.S., Davis R.J., Rakic P., and Flavell R.A. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389 (1997) 865-870
65. Yang D.D., Conze D., Whitmarsh A.J., Barrett T., Davis R.J., Rincon M., and Flavell R.A. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 9 (1998) 575-585
66. Dong C., Yang D.D., Wysk M., Whitmarsh A.J., Davis R.J., and Flavell R.A. Defective T cell differentiation in the absence of Jnk1. Science 282 (1998) 2092-2095
67. Chen N., Nomura M., She Q.B., Ma W.Y., Bode A.M., Wang L., Flavell R.A., and Dong Z. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2- deficient mice. Cancer Res. 61 (2001) 3908-3912
68. She Q.B., Chen N., Bode A.M., Flavell R.A., and Dong Z. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62 (2002) 1343-1348
69. Chen N., She Q.B., Bode A.M., and Dong Z. Differential gene expression profiles of Jnk1- and Jnk2-deficient murine fibroblast cells. Cancer Res. 62 (2002) 1300-1304
70. Cho Y.Y., Bode A.M., Mizuno H., Choi B.Y., Choi H.S., and Dong Z. A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development. Cancer Res. 64 (2004) 3855-3864
71. Toker A., and Cantley L.C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387 (1997) 673-676
72. Cantley L.C., Auger K.R., Carpenter C., Duckworth B., Graziani A., Kapeller R., and Soltoff S. Oncogenes and signal transduction. Cell 64 (1991) 281-302
73. Hu Q., Klippel A., Muslin A.J., Fantl W.J., and Williams L.T. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 268 (1995) 100-102
74. Jhun B.H., Rose D.W., Seely B.L., Rameh L., Cantley L., Saltiel A.R., and Olefsky J.M. Microinjection of the SH2 domain of the 85-kilodalton subunit of phosphatidylinositol 3-kinase inhibits insulin-induced DNA synthesis and c-fos expression. Mol. Cell. Biol. 14 (1994) 7466-7475
75. Stambolic V., Mak T.W., and Woodgett J.R. Modulation of cellular apoptotic potential: Contributions to oncogenesis. Oncogene 18 (1999) 6094-6103
76. Krasilnikov M.A. Phosphatidylinositol-3 kinase dependent pathways: The role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) 65 (2000) 59-67
77. Carpenter C.L., Duckworth B.C., Auger K.R., Cohen B., Schaffhausen B.S., and Cantley L.C. Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem. 265 (1990) 19704-19711
78. Whitman M., Downes C.P., Keeler M., Keller T., and Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332 (1988) 644-646
79. Auger K.R., Serunian L.A., Soltoff S.P., Libby P., and Cantley L.C. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57 (1989) 167-175
80. Stephens L.R., Jackson T.R., and Hawkins P.T. Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: A new intracellular signalling system?. Biochim. Biophys. Acta 1179 (1993) 27-75
81. Huang C., Ma W.Y., and Dong Z. Potentiation of insulin-induced phosphatidylinositol-3 kinase activity by phorbol ester is mediated by protein kinase C epsilon. Cell Signal. 10 (1998) 185-190
82. Huang C., Ma W.Y., Ding M., Li J., Shi X., Castranova V., Vallyathan V., Bode A.M., and Dong Z. Involvement of sphingomyelinase in insulin-induced phosphatidylinositol 3-kinase activation. FASEB J. 15 (2001) 1113-1114
83. Huang C., Schmid P.C., Ma W.Y., Schmid H.H., and Dong Z. Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J. Biol. Chem. 272 (1997) 4187-4194
84. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64 (1995) 280-285
85. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., and Testa J.R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA 93 (1996) 3636-3641
86. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., and Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 89 (1992) 9267-9271
87. Moore S.M., Rintoul R.C., Walker T.R., Chilvers E.R., Haslett C., and Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res. 58 (1998) 5239-5247
88. Barlund M., Monni O., Kononen J., Cornelison R., Torhorst J., Sauter G., Kallioniemi O.-P., and Kallioniemi A. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 60 (2000) 5340-5344
89. Barlund M., Forozan F., Kononen J., Bubendorf L., Chen Y., Bittner M.L., Torhorst J., Haas P., Bucher C., Sauter G., Kallioniemi O.P., and Kallioniemi A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 92 (2000) 1252-1259
90. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., and Schreiber S.L. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377 (1995) 441-446
91. Aoki M., Blazek E., and Vogt P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 98 (2001) 136-141
92. Nave B.T., Ouwens M., Withers D.J., Alessi D.R., and Shepherd P.R. Mammalian target of rapamycin is a direct target for protein kinase B: Identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344 2 (1999) 427-431
93. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., and Abraham R.T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60 (2000) 3504-3513
94. Nomura M., He Z., Koyama I., Ma W.Y., Miyamoto K., and Dong Z. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol. Carcinog. 38 (2003) 25-32
95. Fitzpatrick T.B., Sober A.J., Pearson B.J., and Lew R. Cutaneous carcinogenic effects of sunlight in humans. In: Castellani A. (Ed). "Research in Photobiology" (1976), Plenum, New York 485-490
96. Forbes P.D., Davis R.J., and Urbach F. Experimental ultraviolet carcinogenesis. In: Castellani A. (Ed). "Research in Photobiology" (1976), Plenum, New York 469-478
97. Epstein J.H. Photocarcinogenesis, skin cancer, and aging. J. Am. Acad. Dermatol. 9 (1983) 487-502
98. IARC. Solar and ultraviolet radiation. IARC Monogr. Eval. Carcinog. Risks Hum. 55 (1992) 1-316
99. Kusewitt D.F., Budge C.L., Anderson M.M., Ryan S.L., and Ley R.D. Frequency of ultraviolet radiation-induced mutation at the hprt locus in repair-proficient murine fibroblasts transfected with the denV gene of bacteriophage T4. Photochem. Photobiol. 58 (1993) 450-454
100. Ley R.D. Photoreactivation in humans. Proc. Natl. Acad. Sci. USA 90 (1993) 4337
101. Setlow R.B. The wavelengths in sunlight effective in producing skin cancer: A theoretical analysis. Proc. Natl. Acad. Sci. USA 71 (1974) 3363-3366
102. Bode A.M., and Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci. STKE (2003) RE2
103. Armstrong B.K., and Kricker A. The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B 63 (2001) 8-18
104. de Gruijl F.R., van Kranen H.J., and Mullenders L.H. UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J. Photochem. Photobiol. B 63 (1999) 19-27
105. de Gruijl F.R. Skin cancer and solar UV radiation. Eur. J. Cancer 35 (1999) 2003-2009
106. de Gruijl F.R. Photocarcinogenesis: UVA vs UVB. Methods Enzymol. 319 (2000) 359-366
107. de Laat A., van der Leun J.C., and de Gruijl F.R. Carcinogenesis induced by UVA (365-nm) radiation: The dose-time dependence of tumor formation in hairless mice. Carcinogenesis 18 (1997) 1013-1020
108. Davies R.E., and Forbes P.D. Effect of UV radiation on survival of non-haired mice. Photochem. Photobiol. 43 (1986) 267-274
109. Elments C.A. Cutaneous photocarcinogenesis. In: Mukhtar H. (Ed). "Pharmacology of the Skin" (1992), CRC Press, Boca Raton, FL 389
110. Cole C.A., Forbes P.D., and Davies R.E. An action spectrum for UV photocarcinogenesis. Photochem. Photobiol. 43 (1986) 275-284
111. Kelfkens G., de Gruijl F.R., and van der Leun J.C. The influence of ventral UVA exposure on subsequent tumorigenesis in mice by UVA or UVB irradiation. Carcinogenesis 13 (1992) 2169-2174
112. Scharffetter-Kochanek K., Wlaschek M., Brenneisen P., Schauen M., Blaudschun R., and Wenk J. UV-induced reactive oxygen species in photocarcinogenesis and photoaging. Biol. Chem. 378 (1997) 1247-1257
113. Bender K., Blattner C., Knebel A., Iordanov M., Herrlich P., and Rahmsdorf H.J. UV-induced signal transduction. J. Photochem. Photobiol. B 37 (1997) 1-17
114. Bender K., Gottlicher M., Whiteside S., Rahmsdorf H.J., and Herrlich P. Sequential DNA damage-independent and -dependent activation of NF-kappaB by UV. EMBO J. 17 (1998) 5170-5181
115. Tyrrell R.M. Activation of mammalian gene expression by the UV component of sunlight: From models to reality. Bioessays 18 (1996) 139-148
116. Angel P. The role and regulation of the Jun proteins in response to phorbol ester and UV light. In: Baeuerle P.A. (Ed). "Inducible Gene Expression" (1995), Birkhauser, Boston 62-92
117. Herrlich P., Sachsenmaier C., Radler-Pohl A., Gebel S., Blattner C., and Rahmsdorf H.J. The mammalian UV response: Mechanism of DNA damage induced gene expression. Adv. Enzyme Regul. 34 (1994) 381-395
118. Herrlich P., Ponta H., and Rahmsdorf H.J. DNA damage-induced gene expression: Signal transduction and relation to growth factor signaling. Rev. Physiol. Biochem. Pharmacol. 119 (1992) 187-223
119. Holbrook N.J., and Fornace Jr. A.J. Response to adversity: Molecular control of gene activation following genotoxic stress. New Biol. 3 (1991) 825-833
120. Ronai Z.A., Lambert M.E., and Weinstein I.B. Inducible cellular responses to ultraviolet light irradiation and other mediators of DNA damage in mammalian cells. Cell Biol. Toxicol. 6 (1990) 105-126
121. Punnonen K., and Yuspa S.H. Ultraviolet light irradiation increases cellular diacylglycerol and induces translocation of diacylglycerol kinase in murine keratinocytes. J. Invest. Dermatol. 99 (1992) 221-226
122. Kabuyama Y., Hamaya M., and Homma Y. Wavelength specific activation of PI 3-kinase by UVB irradiation. FEBS Lett. 441 (1998) 297-301
123. Kabuyama Y., Homma M.K., Kurosaki T., and Homma Y. Early signaling events induced by 280-nm UV irradiation. Eur. J. Biochem. 269 (2002) 664-670
124. Kabuyama Y., Homma M.K., Sekimata M., and Homma Y. Wavelength-specific activation of MAP kinase family proteins by monochromatic UV irradiation. Photochem. Photobiol. 73 (2001) 147-152
125. Liebenlist U., Borwn K., and Franzoso G. NF-KB: A mediator of pathogen and stress responses. In: Baeuerle P.A. (Ed). "Inducible Gene Expression" (1995), Birkhauser, Boston 93-141
126. Zhang Y., Liu G., and Dong Z. MSK1 and JNKs mediate phosphorylation of STAT3 in UVA-irradiated mouse epidermal JB6 cells. J. Biol. Chem. 276 (2001) 42534-42542
127. Huang C., Mattjus P., Ma W.Y., Rincon M., Chen N.Y., Brown R.E., and Dong Z. Involvement of nuclear factor of activated T cells activation in UV response: Evidence from cell culture and transgenic mice. J. Biol. Chem. 275 (2000) 9143-9149
128. Adler V., Fuchs S.Y., Kim J., Kraft A., King M.P., Pelling J., and Ronai Z. jun-NH2-terminal kinase activation mediated by UV-induced DNA lesions in melanoma and fibroblast cells. Cell Growth Differ. 6 (1995) 1437-1446
129. Adler V., Pincus M.R., Polotskaya A., Montano X., Friedman F.K., and Ronai Z. Activation of c-Jun-NH2-kinase by UV irradiation is dependent on p21ras. J. Biol. Chem. 271 (1996) 23304-23309
130. Adler V., Schaffer A., Kim J., Dolan L., and Ronai Z. UV irradiation and heat shock mediate JNK activation via alternate pathways. J. Biol. Chem. 270 (1995) 26071-26077
131. Sachsenmaier C., Radler-Pohl A., Zinck R., Nordheim A., Herrlich P., and Rahmsdorf H.J. Involvement of growth factor receptors in the mammalian UVC response. Cell 78 (1994) 963-972
132. Ronai Z.A., and Weinstein I.B. Identification of a UV-induced trans-acting protein that stimulates polyomavirus DNA replication. J. Virol. 62 (1998) 1057-1060
133. Stein B., Angel P., van Dam H., Ponta H., Herrlich P., van der Eb A., and Rahmsdorf H.J. Ultraviolet-radiation induced c-jun gene transcription: Two AP-1 like binding sites mediate the response. Photochem. Photobiol. 55 (1992) 409-415
134. Stein B., Rahmsdorf H.J., Steffen A., Litfin M., and Herrlich P. UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol. Cell. Biol. 9 (1989) 5169-5181
135. Hibi M., Lin A., Smeal T., Minden A., and Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7 (1993) 2135-2148
136. Herr I., van Dam H., and Angel P. Binding of promoter-associated AP-1 is not altered during induction and subsequent repression of the c-jun promoter by TPA and UV irradiation. Carcinogenesis 15 (1994) 1105-1113
137. Devary Y., Gottlieb R.A., Smeal T., and Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 71 (1992) 1081-1091
138. Buzzell R.A. Effects of solar radiation on the skin. Otolaryngol. Clin. North Am. 26 (1993) 1-11
139. Bomser J.A. Selective induction of mitogen-activated protein kinases in human lens epithelial cells by ultraviolet radiation. J. Biochem. Mol. Toxicol. 16 (2002) 33-40
140. Chouinard N., Valerie K., Rouabhia M., and Huot J. UVB-mediated activation of p38 mitogen-activated protein kinase enhances resistance of normal human keratinocytes to apoptosis by stabilizing cytoplasmic p53. Biochem. J 365 (2002) 133-145
141. Klotz L.O., Briviba K., and Sies H. Singlet oxygen mediates the activation of JNK by UVA radiation in human skin fibroblasts. FEBS Lett. 408 (1997) 289-291
142. Klotz L.O., Pellieux C., Briviba K., Pierlot C., Aubry J.M., and Sies H. Mitogen-activated protein kinase (p38-, JNK-, ERK-) activation pattern induced by extracellular and intracellular singlet oxygen and UVA. Eur. J. Biochem. 260 (1999) 917-922
143. Yanase H., Ando H., Horikawa M., Watanabe M., Mori T., and Matsuda N. Possible involvement of ERK 1/2 in UVA-induced melanogenesis in cultured normal human epidermal melanocytes. Pigment Cell Res. 14 (2001) 103-109
144. Englaro W., Derijard B., Ortonne J.P., and Ballotti R. Solar ultraviolet light activates extracellular signal-regulated kinases and the ternary complex factor in human normal keratinocytes. Oncogene 16 (1998) 661-664
145. Djavaheri-Mergny M., and Dubertret L. UV-A-induced AP-1 activation requires the Raf/ERK pathway in human NCTC 2544 keratinocytes. Exp. Dermatol. 10 (2001) 204-210
146. Zhang Y., Dong Z., Bode A.M., Ma W.Y., and Chen N. Induction of EGFR-dependent and EGFR-independent signaling pathways by ultraviolet A irradiation. DNA Cell Biol. 20 (2001) 769-779
147. Zhang Y., Zhong S., Dong Z., Chen N., Bode A.M., and Ma W. UVA induces Ser381 phosphorylation of p90RSK/MAPKAP-K1 via ERK and JNK pathways. J. Biol. Chem. 276 (2001) 14572-14580
148. Zhang Y., Dong Z., Nomura M., Zhong S., Chen N., and Bode A.M. Signal transduction pathways involved in phosphorylation and activation of p70S6K following exposure to UVA irradiation. J. Biol. Chem. 276 (2001) 20913-20923
149. Zhang Y., Ma W.Y., Kaji A., Bode A.M., and Dong Z. Requirement of ATM in UVA-induced signaling and apoptosis. J. Biol. Chem. 277 (2002) 3124-3131
150. Zhang Y., Mattjus P., Schmid P.C., Dong Z., Zhong S., Ma W.Y., Brown R.E., Bode A.M., and Schmid H.H. Involvement of the acid sphingomyelinase pathway in UVA-induced apoptosis. J. Biol. Chem. 276 (2001) 11775-11782
151. Chen W., and Bowden G.T. Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes. Oncogene 18 (1999) 7469-7476
152. Chen W., Tang Q., Gonzales M.S., and Bowden G.T. Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. Oncogene 20 (2001) 3921-3926
153. Maekawa T., Sakura H., Kanei-Ishii C., Sudo T., Yoshimura T., Fujisawa J., Yoshida M., and Ishii S. Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain. EMBO J. 8 (1989) 2023-2028
154. Hai T.W., Liu F., Coukos W.J., and Green M.R. Transcription factor ATF cDNA clones: An extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev. 3 (1989) 2083-2090
155. Fuchs S.Y., and Ronai Z. Ubiquitination and degradation of ATF2 are dimerization dependent. Mol. Cell. Biol. 19 (1999) 3289-3298
156. van Dam H., and Castellazzi M. Distinct roles of Jun:Fos and Jun: ATF dimers in oncogenesis. Oncogene 20 (2001) 2453-2464
157. Fuchs S.Y., Tappin I., and Ronai Z. Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J. Biol. Chem. 275 (2000) 12560-12564
158. Zhu F., Zhang Y., Bode A.M., and Dong Z. Involvement of ERKs and mitogen- and stress-activated protein kinase in UVC-induced phosphorylation of ATF2 in JB6 cells. Carcinogenesis 25 (2004) 1847-1852
159. Coffer P.J., Burgering B.M., Peppelenbosch M.P., Bos J.L., and Kruijer W. UV activation of receptor tyrosine kinase activity. Oncogene 11 (1995) 561-569
160. Knebel A., Rahmsdorf H.J., Ullrich A., and Herrlich P. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J. 15 (1996) 5314-5325
161. Chen N., Ma W., Huang C., and Dong Z. Translocation of protein kinase Cepsilon and protein kinase Cdelta to membrane is required for ultraviolet B-induced activation of mitogen-activated protein kinases and apoptosis. J. Biol. Chem. 274 (1999) 15389-15394
162. Kim H., and Muller W.J. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp. Cell Res. 253 (1999) 78-87
163. Sibilia M., Fleischmann A., Behrens A., Stingl L., Carroll J., Watt F.M., Schlessinger J., and Wagner E.F. The EGF receptor provides an essential survival signal for SOS- dependent skin tumor development. Cell 102 (2000) 211-220
164. Dufner A., and Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res. 253 (1999) 100-109
165. Frodin M., and Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell Endocrinol. 151 (1999) 65-77
166. Kimball S.R., Vary T.C., and Jefferson L.S. Regulation of protein synthesis by insulin. Annu. Rev. Physiol. 56 (1994) 321-348
167. Ostrowski J., Woszczynski M., Kowalczyk P., Wocial T., Hennig E., Trzeciak L., Janik P., and Bomsztyk K. Increased activity of MAP, p70S6, and p90rs kinases is associated with AP-1 activation in spontaneous liver tumours, but not in adjacent tissue in mice. Br. J. Cancer 82 (2000) 1041-1050
168. Downes C.P., and Carter A.N. Phosphoinositide 3-kinase: A new effector in signal transduction?. Cell Signal. 3 (1991) 501-513
169. Gonzales M., and Bowden G.T. The role of PI 3-kinase in the UVB-induced expression of c-fos. Oncogene 21 (2002) 2721-2728
170. Nomura M., Kaji A., He Z., Ma W.Y., Miyamoto K., Yang C.S., and Dong Z. Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway. J. Biol. Chem. 276 (2001) 46624-46631
171. Nomura M., Kaji A., Ma W.Y., Zhong S., Liu G., Bowden G.T., Miyamoto K.I., and Dong Z. Mitogen- and stress-activated protein kinase 1 mediates activation of Akt by ultraviolet B irradiation. J. Biol. Chem. 276 (2001) 25558-25567
172. Zhang Q.S., Maddock D.A., Chen J.P., Heo S., Chiu C., Lai D., Souza K., Mehta S., and Wan Y.S. Cytokine-induced p38 activation feedback regulates the prolonged activation of AKT cell survival pathway initiated by reactive oxygen species in response to UV irradiation in human keratinocytes. Int. J. Oncol. 19 (2001) 1057-1061
173. Rotman G., and Shiloh Y. ATM: A mediator of multiple responses to genotoxic stress. Oncogene 18 (1999) 6135-6144
174. Rotman G., and Shiloh Y. ATM: From gene to function. Hum. Mol. Genet. 7 (2000) 1555-1563
175. Khanna K.K. Cancer risk and the ATM gene: A continuing debate. J. Natl. Cancer Inst. 92 (2000) 795-802
176. Barlow C., Hirotsune S., Paylor R., Liyanage M., Eckhaus M., Collins F., Shiloh Y., Crawley J.N., Ried T., Tagle D., and Wynshaw-Boris A. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 86 (1996) 159-171
177. Kastan M.B., and Lim D.S. The many substrates and functions of ATM. Nature Rev. Mol. Cell. Biol. 1 (2000) 179-186
178. Brown K.D., Barlow C., and Wynshaw-Boris A. Multiple ATM-dependent pathways: An explanation for pleiotropy. Am. J. Hum. Genet. 64 (1999) 46-50
179. Sheikh M.S., and Fornace Jr. A.J. Regulation of translation initiation following stress. Oncogene 18 (1999) 6121-6128
180. Shiloh Y. ATM and ATR: Networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 11 (2001) 71-77
181. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., and Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281 (1998) 1674-1677
182. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., and Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281 (1998) 1677-1679
183. Zhang Y., Cho Y.Y., Petersen B.L., Bode A.M., Zhu F., and Dong Z. Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3. J. Biol. Chem. 278 (2003) 12650-12659
184. Zhang Y., Cho Y.Y., Petersen B.L., Zhu F., and Dong Z. Evidence of STAT1 phosphorylation modulated by MAPKs, MEK1 and MSK1. Carcinogenesis 25 (2004) 1165-1175
185. Kohn A.D., Barthel A., Kovacina K.S., Boge A., Wallach B., Summers S.A., Birnbaum M.J., Scott P.H., Lawrence Jr. J.C., and Roth R.A. Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J. Biol. Chem. 273 (1998) 11937-11943
186. Pause A., Belsham G.J., Gingras A.C., Donze O., Lin T.A., Lawrence Jr. J.C., and Sonenberg N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371 (1994) 762-767
187. Liu G., Zhang Y., Bode A.M., Ma W.Y., and Dong Z. Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in response to UVB irradiation. J. Biol. Chem. 2 (2002) 2
188. Campbell C., Quinn A.G., Ro Y.S., Angus B., and Rees J.L. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J. Invest. Dermatol. 100 (1993) 746-748
189. Tornaletti S., Rozek D., and Pfeifer G.P. The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. Oncogene 8 (1993) 2051-2057
190. Ziegler A., Jonason A.S., Leffell D.J., Simon J.A., Sharma H.W., Kimmelman J., Remington L., Jacks T., and Brash D.E. Sunburn and p53 in the onset of skin cancer. Nature 372 (1994) 773-776
191. She Q.B., Ma W.Y., and Dong Z. Role of MAP kinases in UVB-induced phosphorylation of p53 at serine 20. Oncogene 21 (2002) 1580-1589
192. She Q.B., Chen N., and Dong Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J. Biol. Chem. 275 (2000) 20444-20449
193. Huang C., Ma W.Y., Maxiner A., Sun Y., and Dong Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J. Biol. Chem. 274 (1999) 12229-12235
194. Bulavin D.V., Saito S., Hollander M.C., Sakaguchi K., Anderson C.W., Appella E., and Fornace Jr. A.J. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. Embo J 18 (1999) 6845-6854
195. She Q.B., Ma W.Y., Zhong S., and Dong Z. Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. J. Biol. Chem. 277 (2002) 24039-24048
196. Slominski A., and Pawelek J. Animals under the sun: Effects of ultraviolet radiation on mammalian skin. Clin. Dermatol. 16 (1998) 503-515
197. Okazaki T., Kondo T., Kitano T., and Tashima M. Diversity and complexity of ceramide signalling in apoptosis. Cell Signal. 10 (1998) 685-692
198. Thomson S., Clayton A.L., Hazzalin C.A., Rose S., Barratt M.J., and Mahadevan L.C. The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J. 18 (1999) 4779-4793
199. Zhong S.P., Ma W.Y., and Dong Z. ERKs and p38 kinases mediate ultraviolet B-induced phosphorylation of histone H3 at serine 10. J. Biol. Chem. 275 (2000) 20980-20984
200. Zhong S., Jansen C., She Q.B., Goto H., Inagaki M., Bode A.M., Ma W.Y., and Dong Z. Ultraviolet B-induced phosphorylation of histone H3 at serine 28 is mediated by MSK1. J. Biol. Chem. 276 (2001) 33213-33219
201. Zhong S., Zhang Y., Jansen C., Goto H., Inagaki M., and Dong Z. MAP kinases mediate UVB-induced phosphorylation of histone H3 at serine 28. J. Biol. Chem. 276 (2001) 12932-12937
202. Zhong S., Goto H., Inagaki M., and Dong Z. Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A. Oncogene 22 (2003) 5291-5297
203. Bode A.M., and Dong Z. The paradox of arsenic: Molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 42 (2002) 5-24
204. Bode A.M., and Dong Z. Apoptosis induction by arsenic: Mechanisms of actions and possible clinical applications for treating therapy-resistant cancers. Drug Resistance Updates 3 (2000) 21-29
205. Dong Z. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ. Health Perspect. 110 Suppl. 5 (2002) 757-759
206. Vey N. Arsenic trioxide for the treatment of myelodysplastic syndromes. Expert Opin. Pharmacother. 5 (2004) 613-621
207. Shen Z.X., Shi Z.Z., Fang J., Gu B.W., Li J.M., Zhu Y.M., Shi J.Y., Zheng P.Z., Yan H., Liu Y.F., Chen Y., Shen Y., Wu W., Tang W., Waxman S., De The H., Wang Z.Y., Chen S.J., and Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 101 (2004) 5328-5335
208. Tallmann M.S. Curative therapeutic approaches to APL. Ann. Hematol. 83 Suppl. 1 (2004) S81-S82
209. Douer D., Hu W., Giralt S., Lill M., and DiPersio J. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 8 (2003) 132-140
210. Au W.Y., Lie A.K., Chim C.S., Liang R., Ma S.K., Chan C.H., Mak Y.K., Chen Y.T., So C.C., Yeung Y.M., Yip S.F., Wong L.G., Chan J.C., Liu S.Y., and Kwong Y.L. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann. Oncol. 14 (2003) 752-757
211. Lazo G., Kantarjian H., Estey E., Thomas D., O'Brien S., and Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The M. D. Anderson experience. Cancer 97 (2003) 2218-2224
212. Liu P., and Han Z.C. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: Review of clinical and basic studies. Int. J. Hematol. 78 (2003) 32-39
213. Simeonova P.P., and Luster M.I. Mechanisms of arsenic carcinogenicity: Genetic or epigenetic mechanisms?. J. Environ. Pathol. Toxicol. Oncol. 19 (2000) 281-286
214. Waalkes M.P., Fox D.A., States J.C., Patierno S.R., and McCabe Jr. M.J. Metals and disorders of cell accumulation: Modulation of apoptosis and cell proliferation. Toxicol. Sci. 56 (2000) 255-261
215. Zhao C.Q., Young M.R., Diwan B.A., Coogan T.P., and Waalkes M.P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. USA 94 (1997) 10907-10912
216. Huang C., Ma W.Y., Li J., Goranson A., and Dong Z. Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J. Biol. Chem. 274 (1999) 14595-14601
217. Simeonova P.P., Wang S., Toriuma W., Kommineni V., Matheson J., Unimye N., Kayama F., Harki D., Ding M., Vallyathan V., and Luster M.I. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: Association with activating protein-1 transactivation. Cancer Res. 60 (2000) 3445-3453
218. Parrish A.R., Zheng X.H., Turney K.D., Younis H.S., and Gandolfi A.J. Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol. Sci. 50 (1999) 98-105
219. Cavigelli M., Li W.W., Lin A., Su B., Yoshioka K., and Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 15 (1996) 6269-6279
220. Newton A.C. Protein kinase C. Seeing two domains. Curr. Biol. 5 (1995) 973-976
221. Chen N.Y., Ma W.Y., Huang C., Ding M., and Dong Z. Activation of PKC is required for arsenite-induced signal transduction. J. Environ. Pathol. Toxicol. Oncol. 19 (2000) 297-305
222. He Z., Ma W.Y., Liu G., Zhang Y., Bode A.M., and Dong Z. Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J. Biol. Chem. 278 (2003) 10588-10593
223. Strelkov I.S., and Davie J.R. Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts. Cancer Res. 62 (2002) 75-78
224. Clayton A.L., Rose S., Barratt M.J., and Mahadevan L.C. Phosphoacetylation of histone H3 on c-fos- and c-jun-associated nucleosomes upon gene activation. EMBO J. 19 (2000) 3714-3726
225. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., and Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
226. Bode A.M., and Dong Z. Cancer prevention by food factors through targeting signal transduction pathways. Nutrition 20 (2004) 89-94
227. Bode A.M., and Dong Z. Signal transduction pathways: Targets for green and black tea polyphenols. J. Biochem. Mol. Biol. 36 (2003) 66-77
228. Bode A.M., and Dong Z. Signal transduction pathways: Targets for chemoprevention of skin cancer. Lancet Oncol. 1 (2000) 181-188
229. Bode A.M., and Dong Z. Beneficial effects of resveratrol. In: Bao Y., and Fenwick R. (Eds). "Phytochemicals in Health and Disease" Vol. 12 (2004), Marcel Dekker, New York 257-284
230. Dong Z. Effects of food factors on signal transduction pathways. Biofactors 12 (2000) 17-28
231. Dong Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat. Res. 523-524 (2003) 145-150
232. Dong Z., Nomura M., Huang C., and Ma W.Y. Effects of tea polyphenols on the signal transduction pathways. Adv. Exp. Med. Biol. 492 (2001) 55-67
233. Hong W.K. General keynote: The impact of cancer chemoprevention. Gynecol. Oncol. 88 (2003) S56-S58
234. Goodsell D.S. The molecular perspective: Cyclooxygenase-2. Stem Cells 18 (2000) 227-229
235. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., and Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 99 (2002) 13926-13931
236. Dinchuk J.E., Liu R.Q., and Trzaskos J.M. COX-3: In the wrong frame in mind. Immunol. Lett. 86 (2003) 121
237. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24 (2003) 96-102
238. Turini M.E., and DuBois R.N. Cyclooxygenase-2: A therapeutic target. Annu. Rev. Med. 53 (2002) 35-57
239. Prescott S.M., and Fitzpatrick F.A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta 1470 (2000) M69-M78
240. Marks F., and Furstenberger G. Cancer chemoprevention through interruption of multistage carcinogenesis: The lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer. Eur. J. Cancer 36 (2000) 314-329
241. Marks F., Furstenberger G., and Muller-Decker K. Metabolic targets of cancer chemoprevention: Interruption of tumor development by inhibitors of arachidonic acid metabolism. Recent Results Cancer Res. 151 (1999) 45-67
242. Guan Z., Buckman S.Y., Miller B.W., Springer L.D., and Morrison A.R. Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. J. Biol. Chem. 273 (1998) 28670-28676
243. Dean J.L., Brook M., Clark A.R., and Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 274 (1999) 264-269
244. Subbaramaiah K., Chung W.J., and Dannenberg A.J. Ceramide regulates the transcription of cyclooxygenase-2: Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J. Biol. Chem. 273 (1998) 32943-32949
245. Dong Z., Huang C., Brown R.E., and Ma W.Y. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J. Biol. Chem. 272 (1997) 9962-9970
246. Trevisanato S.I., and Kim Y.I. Tea and health. Nutr. Rev. 58 (2000) 1-10
247. Yang C.S., Chung J.Y., Yang G., Chhabra S.K., and Lee M.J. Tea and tea polyphenols in cancer prevention. J. Nutr. 130 (2000) 472S-478S
248. Huang M.T., Ho C.T., Wang Z.Y., Ferraro T., Finnegan-Olive T., Lou Y.R., Mitchell J.M., Laskin J.D., Newmark H., Yang C.S., et al. Inhibitory effect of topical application of a green tea polyphenol fraction on tumor initiation and promotion in mouse skin. Carcinogenesis 13 (1992) 947-954
249. Yang C.S., and Wang Z.Y. Tea and cancer. J. Natl. Cancer Inst. 85 (1993) 1038-1049
250. Yang C.S., Yang G.Y., Lee M.L., and Chen L. Mechanistic considerations of the inhibition of carcinogenesis by tea. "Proceedings of the International Conference on Food Factor in Cancer Prevention, Tokyo," (1997) 113-117
251. Katiyar S.K., and Mukhtar H. Tea in chemoprevention of cancer: Epidemiologic and experimental studies. Int. J. Oncol. 8 (1996) 221-238
252. Dreosti I.E., Wargovich M.J., and Yang C.S. Inhibition of carcinogenesis by tea: The evidence from experimental studies. Crit. Rev. Food Sci. Nutr. 37 (1997) 761-770
253. Yoshizawa S., Horiuchi T., Fukiji H., Yoshida T., Okuda T., and Sugimura T. Antitumor promoting activity of (-)-epigallocatechin gallate, the main constituent of "tannin" in green tea. Photother. Res. 1 (1987) 44-47
254. Wang Z.Y., Khan W.A., Bickers D.R., and Mukhtar H. Protection against polycyclic aromatic hydrocarbon-induced skin tumor initiation in mice by green tea polyphenols. Carcinogenesis 10 (1989) 411-415
255. Gensler H.L., Timmermann B.N., Valcic S., Wachter G.A., Dorr R., Dvorakova K., and Alberts D.S. Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. Nutr. Cancer 26 (1996) 325-335
256. Ahn H.Y., Hadizadeh K.R., Seul C., Yun Y.P., Vetter H., and Sachinidis A. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol. Biol. Cell 10 (1999) 1093-1104
257. Dong Z., Ma W., Huang C., and Yang C.S. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res. 57 (1997) 4414-4419
258. Chung J.Y., Huang C., Meng X., Dong Z., and Yang C.S. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: Structure-activity relationship and mechanisms involved. Cancer Res. 59 (1999) 4610-4617
259. Chung J.Y., Park J.O., Phyu H., Dong Z., and Yang C.S. Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. FASEB J. 15 (2001) 2022-2024
260. Katiyar S.K., Challa A., McCormick T.S., Cooper K.D., and Mukhtar H. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis 20 (1999) 2117-2124
261. Chen N.Y., Ma W.Y., Yang C.S., and Dong Z. Inhibition of arsenite-induced apoptosis and AP-1 activity by epigallocatechin-3-gallate and theaflavins. J. Environ. Pathol. Toxicol. Oncol. 19 (2000) 287-295
262. Afaq F., Adhami V.M., Ahmad N., and Mukhtar H. Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate. Oncogene 22 (2003) 1035-1044
263. Nomura M., Ma W., Chen N., Bode A.M., and Dong Z. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-kappaB activation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. Carcinogenesis 21 (2000) 1885-1890
264. Nam S., Smith D.M., and Dou Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 276 (2001) 13322-13330
265. Ahmad N., Gupta S., and Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch. Biochem. Biophys. 376 (2000) 338-346
266. Pan M.H., Lin-Shiau S.Y., Ho C.T., Lin J.H., and Lin J.K. Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages. Biochem. Pharmacol. 59 (2000) 357-367
267. Chen C., Shen G., Hebbar V., Hu R., Owuor E.D., and Kong A.N. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis 24 (2003) 1369-1378
268. Hastak K., Gupta S., Ahmad N., Agarwal M.K., Agarwal M.L., and Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22 (2003) 4851-4859
269. Kuo P.L., and Lin C.C. Green tea constituent (-)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J. Biomed. Sci. 10 (2003) 219-227
270. Chung J.H., Han J.H., Hwang E.J., Seo J.Y., Cho K.H., Kim K.H., Youn J.I., and Eun H.C. Dual mechanisms of green tea extract (EGCG)-induced cell survival in human epidermal keratinocytes. Faseb J 17 (2003) 1913-1915
271. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2 (2002) 489-501
272. Pianetti S., Guo S., Kavanagh K.T., and Sonenshein G.E. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 62 (2002) 652-655
273. Gilmore T.D. Clinically relevant findings. J. Clin. Invest. 100 (1997) 2935-2936
274. Lee S.J., Lee I.S., and Mar W. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 activity by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose in murine macrophage cells. Arch. Pharm. Res. 26 (2003) 832-839
275. Park J.W., Choi Y.J., Suh S.I., and Kwon T.K. Involvement of ERK and protein tyrosine phosphatase signaling pathways in EGCG-induced cyclooxygenase-2 expression in Raw 264.7 cells. Biochem. Biophys. Res. Commun. 286 (2001) 721-725
276. Li Z.G., Shimada Y., Sato F., Maeda M., Itami A., Kaganoi J., Komoto I., Kawabe A., and Imamura M. Inhibitory effects of epigallocatechin-3-gallate on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in F344 rats. Int. J. Oncol. 21 (2002) 1275-1283
277. An K.P., Athar M., Tang X., Katiyar S.K., Russo J., Beech J., Aszterbaum M., Kopelovich L., Epstein Jr. E.H., Mukhtar H., and Bickers D.R. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: Implications for therapeutic approaches. Photochem. Photobiol. 76 (2002) 73-80
278. Kundu J.K., Na H.K., Chun K.S., Kim Y.K., Lee S.J., Lee S.S., Lee O.S., Sim Y.C., and Surh Y.J. Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells. J. Nutr. 133 (2003) 3805S-3810S
279. He Z., Ma W.Y., Hashimoto T., Bode A.M., Yang C.S., and Dong Z. Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res. 63 (2003) 4396-4401
280. Hashimoto T., He Z., Ma W.Y., Schmid P.C., Bode A.M., Yang C.S., and Dong Z. Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res. 64 (2004) 3344-3349
281. Dercks W., and Creasy L.L. The influence of fosetyl-A1 on phytoalexin accumulation in the Plasmopara viticola-grapevine interaction. Physiol. Mol. Plant Pathol. 34 (1989) 203-213
282. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
283. Gusman J., Malonne H., and Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22 (2001) 1111-1117
284. Bavaresco L., Fregoni C., Cantu E., and Trevisan M. Stilbene compounds: From the grapevine to wine. Drugs Exp. Clin. Res. 25 (1999) 57-63
285. Dercks W., and Creasy L.L. The significance of stilbene phytoalexins in the Plasmopara viticola-grapevine interaction. Physiol. Mol. Plant Pathol. 34 (1989) 189-202
286. Soleas G.J., Diamandis E.P., and Goldberg D.M. Resveratrol: A molecule whose time has come? And gone?. Clin. Biochem. 30 (1997) 91-113
287. Ahmad N., Adhami V.M., Afaq F., Feyes D.K., and Mukhtar H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer Res. 7 (2001) 1466-1473
288. Surh Y.J., Hurh Y.J., Kang J.Y., Lee E., Kong G., and Lee S.J. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett. 140 (1999) 1-10
289. Kim Y.A., Choi B.T., Lee Y.T., Park D.I., Rhee S.H., Park K.Y., and Choi Y.H. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol. Rep. 11 (2004) 441-446
290. Shih A., Davis F.B., Lin H.Y., and Davis P.J. Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J. Clin. Endocrinol. Metab. 87 (2002) 1223-1232
291. Lu J., Ho C.H., Ghai G., and Chen K.Y. Resveratrol analog, 3,4,5,4′-tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis 22 (2001) 321-328
292. Huang C., Ma W.Y., Goranson A., and Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20 (1999) 237-242
293. Bardeesy N., Beckwith J.B., and Pelletier J. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res. 55 (1995) 215-219
294. She Q.B., Ma W.Y., Wang M., Kaji A., Ho C.T., and Dong Z. Inhibition of cell transformation by resveratrol and its derivatives: Differential effects and mechanisms involved. Oncogene 22 (2003) 2143-2150
295. She Q.B., Bode A.M., Ma W.Y., Chen N.Y., and Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 61 (2001) 1604-1610
296. Mahyar-Roemer M., Katsen A., Mestres P., and Roemer K. Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int. J. Cancer 94 (2001) 615-622
297. Coughlin S.R., Escobedo J.A., and Williams L.T. Role of phosphatidylinositol kinase in PDGF receptor signal transduction. Science 243 (1989) 1191-1194
298. Stein R.C., and Waterfield M.D. PI3-kinase inhibition: A target for drug development?. Mol. Med. Today 6 (2000) 347-357
299. Serunian L.A., Auger K.R., Roberts T.M., and Cantley L.C. Production of novel polyphosphoinositides in vivo is linked to cell transformation by polyomavirus middle T antigen. J. Virol. 64 (1990) 4718-4725
300. Dong Z., Huang C., and Ma W.Y. PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer. Anticancer Res. 19 (1999) 3743-3747
301. Huang C., Ma W.Y., Hecht S.S., and Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase. Cancer Res. 57 (1997) 2873-2878 [published erratum appears in Cancer Res. 57(22), 5198 (1997)]
302. Pozo-Guisado E., Lorenzo-Benayas M.J., and Fernandez-Salguero P.M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: Relevance in cell proliferation. Int. J. Cancer 109 (2004) 167-173
303. Nicolini G., Rigolio R., Scuteri A., Miloso M., Saccomanno D., Cavaletti G., and Tredici G. Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem. Int. 42 (2003) 419-429
304. Billard C., Izard J.C., Roman V., Kern C., Mathiot C., Mentz F., and Kolb J.P. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk. Lymphoma 43 (2002) 1991-2002
305. Holmes-McNary M., and Baldwin Jr. A.S. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res. 60 (2000) 3477-3483
306. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M., Pezzuto J.M., and Dannenberg A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273 (1998) 21875-21882
307. Mutoh M., Takahashi M., Fukuda K., Matsushima-Hibiya Y., Mutoh H., Sugimura T., and Wakabayashi K. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 21 (2000) 959-963
308. Garcia-Garcia J., Micol V., de Godos A., and Gomez-Fernandez J.C. The cancer chemopreventive agent resveratrol is incorporated into model membranes and inhibits protein kinase C alpha activity. Arch. Biochem. Biophys. 372 (1999) 382-388
309. Cosgrove D.J. "Inositol Phosphates, Their Chemistry, Biochemistry and Physiology" (1980), Elsevier, Amsterdam/New York
310. Bunce C.M., French P.J., Allen P., Mountford J.C., Moor B., Greaves M.F., Michell R.H., and Brown G. Comparison of the levels of inositol metabolites in transformed haemopoietic cells and their normal counterparts. Biochem. J 289 3 (1993) 667-673
311. Szwergold B.S., Graham R.A., and Brown T.R. Observation of inositol pentakis- and hexakis-phosphates in mammalian tissues by 31P NMR. Biochem. Biophys. Res. Commun. 149 (1987) 874-881
312. Vucenik I., Tomazic V.J., Fabian D., and Shamsuddin A.M. Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. Cancer Lett. 65 (1992) 9-13
313. Pretlow T.O., O'Riorda M.A., and Pretlow T.G. Colon carcinogenesis is inhibited more effectively by phytate than by selenium if F344 rats given 30 mg/kg azoxymethane. In: Jacobs M.M. (Ed). "Diet and Cancer Markers, Prevention and Treatment" (1994), Plenum Press, New York 244
314. Estensen R.D., and Wattenberg L.W. Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 14 (1993) 1975-1977
315. Shamsuddin A.M., and Vucenik I. Mammary tumor inhibition by IP6: A review. Anticancer Res. 19 (1999) 3671-3674
316. Vucenik I., and Shamsuddin A.M. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: From laboratory to clinic. J. Nutr. 133 (2003) 3778S-3784S
317. Gupta K.P., Singh J., and Bharathi R. Suppression of DMBA-induced mouse skin tumor development by inositol hexaphosphate and its mode of action. Nutr. Cancer 46 (2003) 66-72
318. Saied I.T., and Shamsuddin A.M. Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line. Anticancer Res. 18 (1998) 1479-1484
319. Ishikawa T., Nakatsuru Y., Zarkovic M., and Shamsuddin A.M. Inhibition of skin cancer by IP6 in vivo: Initiation-promotion model. Anticancer Res. 19 (1999) 3749-3752
320. Ferry S., Matsuda M., Yoshida H., and Hirata M. Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkappaB-mediated cell survival pathway. Carcinogenesis 23 (2002) 2031-2041
321. Agarwal C., Dhanalakshmi S., Singh R.P., and Agarwal R. Inositol hexaphosphate inhibits constitutive activation of NF-kappa B in androgen-independent human prostate carcinoma DU145 cells. Anticancer Res. 23 (2003) 3855-3861
322. Singh R.P., Agarwal C., and Agarwal R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: Modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 24 (2003) 555-563
323. Singh R.P., Sharma G., Mallikarjuna G.U., Dhanalakshmi S., Agarwal C., and Agarwal R. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: Induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin. Cancer Res. 10 (2004) 244-250
324. Sharma G., Singh R.P., and Agarwal R. Growth inhibitory and apoptotic effects of inositol hexaphosphate in transgenic adenocarcinoma of mouse prostate (TRAMP-C1) cells. Int. J. Oncol. 23 (2003) 1413-1418
325. Deliliers G.L., Servida F., Fracchiolla N.S., Ricci C., Borsotti C., Colombo G., and Soligo D. Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells. Br. J. Haematol. 117 (2002) 577-587
326. El-Sherbiny Y.M., Cox M.C., Ismail Z.A., Shamsuddin A.M., and Vucenik I. G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). Anticancer Res. 21 (2001) 2393-2403
327. Huang C., Ma W.Y., Li J., Hecht S.S., and Dong Z. Essential role of p53 in phenethyl isothiocyanate-induced apoptosis. Cancer Res. 58 (1998) 4102-4106
328. Kong A.N., Mandlekar S., Yu R., Lei W., and Fasanmande A. Pharmacodynamics and toxicodynamics of drug action: Signaling in cell survival and cell death. Pharm. Res. 16 (1999) 790-798
329. Patten E.J., and DeLong M.J. Temporal effects of the detoxification enzyme inducer, benzyl isothiocyanate: Activation of c-Jun N-terminal kinase prior to the transcription factors AP-1 and NFkappaB. Biochem. Biophys. Res. Commun. 257 (1999) 149-155
330. Chen Y.R., Wang W., Kong A.N., and Tan T.H. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J. Biol. Chem. 273 (1998) 1769-1775
331. Bode A.M., Ma W.Y., Surh Y.J., and Dong Z. Inhibition of epidermal growth factor-induced cell transformation and activator protein 1 activation by [6]-gingerol. Cancer Res. 61 (2001) 850-853
332. Nomura M., Kaji A., Ma W., Miyamoto K., and Dong Z. Suppression of cell transformation and induction of apoptosis by caffeic acid phenethyl ester. Mol. Carcinog. 31 (2001) 83-89
333. Liu G., Bode A., Ma W.Y., Sang S., Ho C.T., and Dong Z. Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line. Cancer Res. 61 (2001) 5749-5756
334. Liu G., Bibus D.M., Bode A.M., Ma W.Y., Holman R.T., and Dong Z. Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells. Proc. Natl. Acad. Sci. USA 98 (2001) 7510-7515
335. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat. Res. 428 (1999) 305-327
336. Lee E., Park K.K., Lee J.M., Chun K.S., Kang J.Y., Lee S.S., and Surh Y.J. Suppression of mouse skin tumor promotion and induction of apoptosis in HL-60 cells by Alpinia oxyphylla Miquel (Zingiberaceae). Carcinogenesis 19 (1998) 1377-1381
337. Lee E., and Surh Y.J. Induction of apoptosis in HL-60 cells by pungent vanilloids, [6]-gingerol and [6]-paradol. Cancer Lett. 134 (1998) 163-168
338. Surh Y.J., Lee E., and Lee J.M. Chemoprotective properties of some pungent ingredients present in red pepper and ginger. Mutat. Res. 402 (1998) 259-267
339. Surh Y.J. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: A short review. Food Chem. Toxicol. 40 (2002) 1091-1097
340. Yoshimi N., Wang A., Morishita Y., Tanaka T., Sugie S., Kawai K., Yamahara J., and Mori H. Modifying effects of fungal and herb metabolites on azoxymethane-induced intestinal carcinogenesis in rats. Jpn. J. Cancer Res. 83 (1992) 1273-1278
341. Vimala S., Norhanom A.W., and Yadav M. Anti-tumour promoter activity in Malaysian ginger rhizobia used in traditional medicine. Br. J. Cancer 80 (1999) 110-116
342. Kapadia G.J., Azuine M.A., Tokuda H., Hang E., Mukainaka T., Nishino H., and Sridhar R. Inhibitory effect of herbal remedies on 12-O-tetradecanoylphorbol-13-acetate-promoted Epstein-Barr virus early antigen activation. Pharmacol. Res. 45 (2002) 213-220
343. Katiyar S.K., Agarwal R., and Mukhtar H. Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome. Cancer Res. 56 (1996) 1023-1030
344. Park K.K., Chun K.S., Lee J.M., Lee S.S., and Surh Y.J. Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Lett. 129 (1998) 139-144
345. Chung W.Y., Jung Y.J., Surh Y.J., Lee S.S., and Park K.K. Antioxidative and antitumor promoting effects of [6]-paradol and its homologs. Mutat. Res. 496 (2001) 199-206
346. Thatte U., Bagadey S., and Dahanukar S. Modulation of programmed cell death by medicinal plants. Cell Mol. Biol. 46 (2000) 199-214
347. Keum Y.S., Kim J., Lee K.H., Park K.K., Surh Y.J., Lee J.M., Lee S.S., Yoon J.H., Joo S.Y., Cha I.H., and Yook J.I. Induction of apoptosis and caspase-3 activation by chemopreventive [6]-paradol and structurally related compounds in KB cells. Cancer Lett. 177 (2002) 41-47
348. Miyoshi N., Nakamura Y., Ueda Y., Abe M., Ozawa Y., Uchida K., and Osawa T. Dietary ginger constituents, galanals A and B, are potent apoptosis inducers in human T lymphoma Jurkat cells. Cancer Lett. 199 (2003) 113-119
349. Koo K.L., Ammit A.J., Tran V.H., Duke C.C., and Roufogalis B.D. Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation. Thromb. Res. 103 (2001) 387-397
350. Tjendraputra E., Tran V.H., Liu-Brennan D., Roufogalis B.D., and Duke C.C. Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. Bioorg. Chem. 29 (2001) 156-163
351. Huang M.T., Ma W., Yen P., Xie J.G., Han J., Frenkel K., Grunberger D., and Conney A.H. Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Carcinogenesis 17 (1996) 761-765
352. Nagaoka T., Banskota A.H., Tezuka Y., Saiki I., and Kadota S. Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26-L5 carcinoma cell line. Bioorg. Med. Chem. 10 (2002) 3351-3359
353. Nagaoka T., Banskota A.H., Tezuka Y., Harimaya Y., Koizumi K., Saiki I., and Kadota S. Inhibitory effects of caffeic acid phenethyl ester analogues on experimental lung metastasis of murine colon 26-L5 carcinoma cells. Biol. Pharm. Bull. 26 (2003) 638-641
354. Hung M.W., Shiao M.S., Tsai L.C., Chang G.G., and Chang T.C. Apoptotic effect of caffeic acid phenethyl ester and its ester and amide analogues in human cervical cancer ME180 cells. Anticancer Res. 23 (2003) 4773-4780
355. Shigeoka Y., Igishi T., Matsumoto S., Nakanishi H., Kodani M., Yasuda K., Hitsuda Y., and Shimizu E. Sulindac sulfide and caffeic acid phenethyl ester suppress the motility of lung adenocarcinoma cells promoted by transforming growth factor-beta through Akt inhibition. J. Cancer Res. Clin. Oncol. 130 (2004) 146-152
356. Carrasco-Legleu C.E., Marquez-Rosado L., Fattel-Fazenda S., Arce-Popoca E., Perez-Carreon J.I., and Villa-Trevino S. Chemoprotective effect of caffeic acid phenethyl ester on promotion in a medium-term rat hepatocarcinogenesis assay. Int. J. Cancer 108 (2004) 488-492
357. Ozyurt H., Sogut S., Yildirim Z., Kart L., Iraz M., Armutcu F., Temel I., Ozen S., Uzun A., and Akyol O. Inhibitory effect of caffeic acid phenethyl ester on bleomycine-induced lung fibrosis in rats. Clin. Chim. Acta 339 (2004) 65-75
358. Lee Y.J., Kuo H.C., Chu C.Y., Wang C.J., Lin W.C., and Tseng T.H. Involvement of tumor suppressor protein p53 and p38 MAPK in caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. Biochem. Pharmacol. 66 (2003) 2281-2289
359. Song Y.S., Park E.H., Hur G.M., Ryu Y.S., Lee Y.S., Lee J.Y., Kim Y.M., and Jin C. Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and enzyme activity. Cancer Lett. 175 (2002) 53-61
360. Watabe M., Hishikawa K., Takayanagi A., Shimizu N., and Nakaki T. Caffeic acid phenethyl ester induces apoptosis by inhibition of NFkappaB and activation of Fas in human breast cancer MCF-7 cells. J. Biol. Chem. 279 (2004) 6017-6026
361. Hirazumi A., Furusawa E., Chou S.C., and Hokama Y. Immunomodulation contributes to the anticancer activity of Morinda citrifolia (noni) fruit juice. Proc. West Pharmacol. Soc. 39 (1996) 7-9
362. Wang M., Kikuzaki H., Csiszar K., Boyd C.D., Maunakea A., Fong S.F., Ghai G., Rosen R.T., Nakatani N., and Ho C.T. Novel trisaccharide fatty acid ester identified from the fruits of Morinda citrifolia (noni). J. Agric. Food Chem. 47 (1999) 4880-4882
363. Hirazumi A., Furusawa E., Chou S.C., and Hokama Y. Anticancer activity of Morinda citrifolia (noni) on intraperitoneally implanted Lewis lung carcinoma in syngeneic mice. Proc. West Pharmacol. Soc. 37 (1994) 145-146
364. Holman R., and Mohrhauer H. A hypothesis involving competitive inhibitions in the metabolism of polyunsaturated fatty acids. Acta Chem. Scand. 17 (1963) S84-S90
365. Yen, A., Black, H.S., Tschen, J., Effect of dietary omega-3 and omega-6 fatty acid sources on PUVA-induced cutaneous toxicity and tumorigenesis in the hairless mouse. Arch. Dermatol. Res.286, 331-336.
366. Reddy B.S. Chemoprevention of colon cancer by dietary fatty acids. Cancer Metastasis Rev. 13 (1994) 285-302
367. Parkinson A.J., Cruz A.L., Heyward W.L., Bulkow L.R., Hall D., Barstaed L., and Connor W.E. Elevated concentrations of plasma omega-3 polyunsaturated fatty acids among Alaskan Eskimos. Am. J. Clin. Nutr. 59 (1994) 384-388
368. Caygill C.P., Charlett A., and Hill M.J. Fat, fish, fish oil and cancer. Br. J. Cancer 74 (1996) 159-164
369. Hillyard L.A., and Abraham S. Effect of dietary polyunsaturated fatty acids on growth of mammary adenocarcinomas in mice and rats. Cancer Res. 39 (1979) 4430-4437
370. Sauer L.A., Dauchy R.T., and Blask D.E. Mechanism for the antitumor and anticachectic effects of n-3 fatty acids. Cancer Res. 60 (2000) 5289-5295
371. Rose D.P., and Connolly J.M. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol. Ther. 83 (1999) 217-244
372. Rose D.P. Effects of dietary fatty acids on breast and prostate cancers: Evidence from in vitro experiments and animal studies. Am. J. Clin. Nutr. 66 (1997) 1513S-1522S
373. Rose D.P. Dietary fatty acids and cancer. Am. J. Clin. Nutr. 66 (1997) 998S-1003S
374. Melville J.C., and Ryan C.A. Chymotrypsin inhibitor I from potatoes: Large scale preparation and characterization of its subunit components. J. Biol. Chem. 247 (1972) 3445-3453
375. Bryant J., Green T.R., Gurusaddaiah T., and Ryan C.A. Proteinase inhibitor II from potatoes: Isolation and characterization of its protomer components. Biochemistry 15 (1976) 3418-3424
376. Bergey D.R., Howe G.A., and Ryan C.A. Polypeptide signaling for plant defensive genes exhibits analogies to defense signaling in animals. Proc. Natl. Acad. Sci. USA 93 (1996) 12053-12058
377. Conconi A., Smerdon M.J., Howe G.A., and Ryan C.A. The octadecanoid signalling pathway in plants mediates a response to ultraviolet radiation. Nature 383 (1996) 826-829
378. Billings P.C., Morrow A.R., Ryan C.A., and Kennedy A.R. Inhibition of radiation-induced transformation of C3H/10T1/2 cells by carboxypeptidase inhibitor 1 and inhibitor II from potatoes. Carcinogenesis 10 (1989) 687-691